AITL patient frail or elderly unfit for full-dose CHOEP / CHP-Bv induction: ECOG ≥3, OR a...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-AITL-FRAILTY-AGE |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-AITL |
| Sources | SRC-ESMO-PTCL-2024 SRC-NCCN-BCELL-2025 |
Red Flag Origin
| Definition | AITL patient frail or elderly unfit for full-dose CHOEP / CHP-Bv induction: ECOG ≥3, OR age ≥75, OR (age ≥70 + ≥2 comorbidities + albumin <3.5), OR explicit clinical assessment "unfit for intensive chemotherapy". AITL median age at diagnosis is 65-70 — most patients fall close to this threshold. |
|---|---|
| Clinical direction | de-escalate |
| Category | frailty-age |
Trigger Logic
{
"any_of": [
{
"comparator": ">=",
"finding": "ecog",
"threshold": 3
},
{
"comparator": ">=",
"finding": "age",
"threshold": 75
},
{
"finding": "fit_for_intensive_chemo",
"value": false
},
{
"all_of": [
{
"comparator": ">=",
"finding": "age",
"threshold": 70
},
{
"comparator": ">=",
"finding": "comorbidity_count",
"threshold": 2
},
{
"comparator": "<",
"finding": "albumin_g_dl",
"threshold": 3.5
}
]
}
],
"type": "composite_score"
}
Notes
AITL is the second-most-common PTCL subtype and predominantly affects older adults (median 65-70). ECHELON-2 (brentuximab-CHP) included patients up to age 80 but post-hoc subgroups suggest tolerability concern >75. Frailty options: CHOP (drop etoposide), mini-CHOP (50-60% doses) per GELA LNH03-7B paradigm extrapolated from DLBCL, GEM-P (gemcitabine + methylprednisolone + cisplatin) as outpatient alternative, or romidepsin-monotherapy in unfit relapse. Geriatric assessment (G8 / CGA) prior to regimen selection. Direction "de-escalate" conflicts with HIGH-RISK-BIOLOGY "intensify" — engine surfaces conflict to MDT.
Used By
No reverse references found in the YAML corpus.